AMG 562 20170533 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma (Aktiv)
B-NHL 2013 B-NHL 2013 - Behandlungsprotokoll der NHL-BFM und der NOPHO-Studiengruppen für reife aggressive B-Zell-Lymphome und -Leukämien bei Kindern und Jugendlichen (Aktiv)
CZAR-1 fficacy and safety of Carfilzomib in combination with Ibrutinib for patients with Waldenström's macroglobulinemia (CZAR-1) (Aktiv)
GO29781 A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)
JCAR017-BCM-004 JE A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) (Aktiv)
POLE-1 Efficacy of pembrolizumab in patients with marginal zone lymphoma (Aktiv)
NHL 3-2004 Therapy Optimisation for the Treatment of Hairy Cell Leukemia (Aktiv)
OLYMP-1 Obinutuzumab in Marginal Zone Lymphoma (Aktiv)
Zweitlinie oder später
67856633LYM1001 A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)
CHARLY Study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma (Aktiv)
CNIR178X2201 Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)
CVOB560A12101 A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma. (Aktiv)
GC-LTFU-001 Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)
GOAL Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) incombination with PixantrOne (Aktiv)
KEYNOTE-348 Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (Aktiv)
Lymrit-37-01 A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma. (Aktiv)
M13-833 A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies (Aktiv)
NP40126 A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas (Aktiv)
R1979-ONC-1625 Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (Aktiv)
REGN1979-HM-1333 This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)